title: Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.
authors.affiliation: St. Vincent's Hospital, Melbourne, Australia.
authors.forename: Philip A
authors.initials: PA
authors.lastname: Thompson
authors.forename: Constantine S
authors.initials: CS
authors.lastname: Tam
authors.forename: Karin
authors.initials: K
authors.lastname: Thursky
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000821:virology*; D011379:Prognosis; D000069283:Rituximab; D015996:Survival Rate; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab